世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界のオリゴヌクレオチド治療市場 2018-2022 年

Global Oligonucleotide Therapeutics Market 2018-2022

IRTNTR23202

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年6月US$2,500
シングルユーザライセンス
103

サマリー

この調査レポートは世界のオリゴヌクレオチド治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Oligonucleotide Therapeutics
Oligonucleotides are short nucleotides sequences of DNA or RNA molecules called oligomers. Oligonucleotide therapeutics target and inhibit the expression of certain diseases-causing genes, thus forming a new class of therapeutics to treat chronic diseases.
Technavio’s analysts forecast the Global Oligonucleotide Therapeutics Market to grow at a CAGR of 9.52% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the oligonucleotide therapeutics market. To calculate the market size, the report considers the revenue generated from the sales of oligonucleotide therapeutics.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, oligonucleotide therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Arrowhead Pharmaceuticals
- GlaxoSmithKline
- Ionis Pharmaceuticals
- miRagen Therapeutics
- Sarepta Therapeutics

Market driver
- Increased availability of approved drugs
- For a full, detailed list, view our report
Market challenge
- Inherent challenges with oligonucleotide therapies
- For a full, detailed list, view our report

Market trend
- Increasing M&A
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
? Market ecosystem
? Market characteristics
? Market segmentation analysis
PART 05: MARKET SIZING
? Market definition
? Market sizing 2017
? Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
? Bargaining power of buyers
? Bargaining power of suppliers
? Threat of new entrants
? Threat of substitutes
? Threat of rivalry
? Market condition
PART 07: MARKET SEGMENTATION BY APPLICATION
? Segmentation by application
? Comparison by application
? Neurological disorders ? Market size and forecast 2017-2022
? Cancer ? Market size and forecast 2017-2022
? Others ? Market size and forecast 2017-2022
? Market opportunity by application
PART 08: MARKET SEGMENTATION BY TECHNOLOGY
? Segmentation by technology
? Comparison by technology
? Antisense/RNAi oligonucleotides ? Market size and forecast 2017-2022
? Others ? Market size and forecast 2017-2022
? Market opportunity by technology
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
? Geographical segmentation
? Regional comparison
? Americas ? Market size and forecast 2017-2022
? EMEA ? Market size and forecast 2017-2022
? APAC ? Market size and forecast 2017-2022
? Key leading countries
? Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
? Market drivers
? Market challenges
PART 13: MARKET TRENDS
? Increasing M&A
? Advances in DNA sequencing increases use of microfluidic techniques
? Increasing drugs in pipeline
PART 14: VENDOR LANDSCAPE
? Overview
? Landscape disruption
PART 15: VENDOR ANALYSIS
? Vendors covered
? Vendor classification
? Market positioning of vendors
? Arrowhead Pharmaceuticals
? GlaxoSmithKline
? Ionis Pharmaceuticals
? miRagen Therapeutics
? Sarepta Therapeutics
PART 16: APPENDIX
? List of abbreviations


Exhibit 01: Related market
Exhibit 02: Market characteristics
Exhibit 03: Market segments
Exhibit 04: Market definition - Inclusions and exclusions checklist
Exhibit 05: Market size 2017
Exhibit 06: Validation techniques employed for market sizing 2017
Exhibit 07: Global ? Market size and forecast 2017-2022 ($ mn)
Exhibit 08: Global ? Year-over-year growth 2018-2022 (%)
Exhibit 09: Five forces analysis 2017
Exhibit 10: Five forces analysis 2022
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2017
Exhibit 17: Application ? Market share 2017-2022 (%)
Exhibit 18: Comparison by application
Exhibit 19: Neurological disorders ? Market size and forecast 2017-2022 ($ mn)
Exhibit 20: Neurological disorders ? Year-over-year growth 2018-2022 (%)
Exhibit 21: Cancer ? Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Cancer ? Year-over-year growth 2018-2022 (%)
Exhibit 23: Others ? Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Others ? Year-over-year growth 2018-2022 (%)
Exhibit 25: Market opportunity by application
Exhibit 26: Technology ? Market share 2017-2022 (%)
Exhibit 27: Comparison by technology
Exhibit 28: Antisense/RNAi oligonucleotides ? Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Antisense/RNAi oligonucleotides ? Year-over-year growth 2018-2022 (%)
Exhibit 30: Others ? Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Others ? Year-over-year growth 2018-2022 (%)
Exhibit 32: Market opportunity by technology
Exhibit 33: Customer landscape
Exhibit 34: Global ? Market share by geography 2017-2022 (%)
Exhibit 35: Regional comparison
Exhibit 36: Americas ? Market size and forecast 2017-2022 ($ mn)
Exhibit 37: Americas ? Year-over-year growth 2018-2022 (%)
Exhibit 38: EMEA ? Market size and forecast 2017-2022 ($ mn)
Exhibit 39: EMEA ? Year-over-year growth 2018-2022 (%)
Exhibit 40: APAC ? Market size and forecast 2017-2022 ($ mn)
Exhibit 41: APAC ? Year-over-year growth 2018-2022 (%)
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Cost of sequencing per genome in $ (2001-2015)
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Arrowhead Pharmaceuticals overview
Exhibit 51: Arrowhead Pharmaceuticals ? Product segments
Exhibit 52: Arrowhead Pharmaceuticals ? Organizational developments
Exhibit 53: Arrowhead Pharmaceuticals ? Key offerings
Exhibit 54: GlaxoSmithKline overview
Exhibit 55: GlaxoSmithKline ? Business segments
Exhibit 56: GlaxoSmithKline ? Organizational developments
Exhibit 57: GlaxoSmithKline ? Geographic focus
Exhibit 58: GlaxoSmithKline ? Segment focus
Exhibit 59: GlaxoSmithKline ? Key offerings
Exhibit 60: Ionis Pharmaceuticals overview
Exhibit 61: Ionis Pharmaceuticals ? Business segments
Exhibit 62: Ionis Pharmaceuticals ? Organizational developments
Exhibit 63: Ionis Pharmaceuticals ? Segment focus
Exhibit 64: Ionis Pharmaceuticals ? Key offerings
Exhibit 65: miRagen Therapeutics overview
Exhibit 66: miRagen Therapeutics ? Business segments
Exhibit 67: miRagen Therapeutics ? Organizational developments
Exhibit 68: miRagen Therapeutics ? Key offerings
Exhibit 69: Sarepta Therapeutics overview
Exhibit 70: Sarepta Therapeutics ? Business segments
Exhibit 71: Sarepta Therapeutics ? Organizational developments
Exhibit 72: Sarepta Therapeutics ? Key offerings

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る